6 results about "Genitourinary system" patented technology

The present invention provides a mucosa-based non-invasive gene therapy with a recombinant vector. The recombinant region of the recombinant vector comprises a coding sequence of at least one therapeutic gene. The recombinant vector is administered to the respiratory system, the digestive system, the genitourinary system, and the eyes via the mucosa, for preventing and / or treating a disease.

Discloses herein are methods of treating diseases, disorders, or conditions related to the female genitourinary system. Also disclosed are compositions and delivery devices with therapeutic use in the treatment. Specifically, aspects of the disclosure relate to a degradable and biocompatible device that effectively delivers a therapeutic agent to a subject in need thereof comprising at least one of a stem cell or / and an extracellular vesicle derived thereof, wherein the cells are grown in conditioned medium comprising estrogen or were primed with estrogen, or any combination thereof.

Provided are methods for detecting urogenital malignancies in dogs. In some embodiments, the methods include identifying a deletion or single nucleotide substitution within a BRAF gene and / or within a MAP2K1 gene present in or isolated from a biological sample from a. dog, wherein the presence of the deletion or single nucleotide substitution within the BRAF gene and / or within the MAP2K1 gene detects a urogenital malignancy, optionally transitional cell carcinoma / urothelial carcinoma, in the dog. In some embodiments, the deletion is within exon 12 of BRAF gene, optionally within the amino acid sequence KMLNVTAPTPQQL (SEQ ID NO: 3), and / or in within exon 2 or 3 of a M.AP2K1 gene, optionally within the amino acid sequence FLTQKQKVGE (SEQ ID NO: 4).

The invention discloses a deep learning and behavior boosting theory-based accurate prediction system for a urogenital system infection risk of SGLT2 inhibitor hypoglycemic drugs. According to the invention, through the innovative structural design of the deep learning risk prediction module, the individualized accurate prediction of the SGLT2 inhibitor hypoglycemic drug related urogenital infection risk is realized. The module adopts a hybrid neural network of a Transform encoder and a gating circulation unit, can process multi-source clinical data of a patient at the same time, not only identifies deep association between static characteristics such as demostatistics and medical history and infection risks, but also captures fluctuation rules of dynamic sequences such as laboratory inspection indexes along with time. The deep mining capability of a high-dimensional complex data mode breaks through the limitation that a traditional scoring tool depends on limited indexes and fixed weights, differentiated risk levels can be output according to the unique clinical trajectory of each patient, and an accurate decision basis is provided for subsequent intervention.

1. The name of the design product: urogenital system therapeutic instrument. 2. The use of the design product: urogenital system therapeutic instrument. 3. The design points of the design product: the combination of shape, pattern and color. 4. The picture or photo that best shows the design points: perspective view. 5. The design claimed contains color.

A method for treating the gastrointestinal or a urogenital system of a subject with prebiotic nutrients and probiotic bacteria is provided. Multi-chamber products are described which include at least two chambers wherein probiotic bacteria or human microbiome transplants are contained in one or more inner chambers and wherein prebiotic nutrients are contained in an outer chamber, the outer chamber completely enclosing the inner chamber(s). One or both chambers may contain a pharmaceutically acceptable material that is solid outside the human body when in a dry environment, but that melts at internal body temperature. The products may be administered by oral, rectal, vaginal, or urethral routes.